• S Berardis, A Verroken, A Vetillart, C Struyf, M Gilbert, D Gruson, and S Gohy.
• Centre de référence pour la mucoviscidose, Cliniques universitaires Saint-Luc, Brussels, Belgium; Department of Pediatrics, Cliniques universitaires Saint-Luc, Brussels, Belgium.
• J. Cyst. Fibros. 2020 Nov 1; 19 (6): 872-874.

BackgroundIn Belgium, COVID-19 epidemy began on February 4, 2020 with a peak on April 10, 2020. Patients with cystic fibrosis (CF) followed in the Cliniques universitaires Saint-Luc were rapidly isolated before the government lockdown.MethodsAfter the peak of the epidemy, we measured anti-SARS-CoV-2 IgM and IgG antibodies in 149 patients and collected clinical data.ResultsOnly 3 asymptomatic patients presented IgG against the virus. In one patient hospitalized for COVID-19 (positive molecular testing), we did not detect any anti-SARS-CoV-2 antibodies, as in thirty-five other symptomatic patients considered as possible cases.ConclusionsEven if respiratory symptoms linked to CF are frequent and compatible with COVID-19, anti-SARS-CoV-2 IgG antibodies were detected only in 3 asymptomatic patients. This reassuring study concerning the risk of COVID-19 in patients with CF illustrates the difficulty to distinguish COVID-19 symptoms from respiratory exacerbations and the need of generalized molecular testing to make a precise diagnosis.Copyright © 2020. Published by Elsevier B.V.

35 keywords...

hide…